Prism Medico and Pharmacy Limited’s Board of Directors convened on August 12, 2026, to approve the unaudited standalone financial results for the quarter ended June 30, 2026. The meeting, held from 1:30 PM to 3:30 PM IST, also saw the approval of the Limited Review Report signed by the company’s auditors. The results reflect the company’s financial performance for the specified period.
Board Meeting Approves Financials
Prism Medico and Pharmacy Limited announced that its Board of Directors met on Wednesday, August 12, 2026. The meeting, which commenced at 01:30 PM and concluded at 03:30 PM, was held at the company’s registered office in Kala Amb, Sirmaur, Himachal Pradesh. During this meeting, the Board considered and approved the unaudited standalone financial results for the quarter ended June 30, 2026.
Key Approvals and Review
In addition to approving the financial results, the Board also gave its assent to the accompanying Limited Review Report, which was duly signed by the company’s auditors. This report provides an independent review of the financial statements. The Board’s resolution specifically states that the unaudited standalone financial results, as reviewed by the Audit Committee, are hereby approved. Furthermore, Mr. Davender Singh, Director, was authorized to sign the statement of accounts and undertake any necessary actions to implement this resolution.
Financial Highlights for Q1 FY2026
The standalone financial results for the quarter ended June 30, 2026, indicate total revenue from operations of ₹9.06 Lakhs, a decrease from ₹158.87 Lakhs in the previous year’s comparable period. Total expenses for the quarter amounted to ₹14.89 Lakhs. Consequently, the company reported a profit/(loss) before tax of ₹(5.83) Lakhs for the quarter. Net profit/(loss) for the period stood at ₹(5.83) Lakhs. Total comprehensive income for the quarter was also reported as ₹(5.83) Lakhs.
Source: BSE
